269 related articles for article (PubMed ID: 30108064)
1. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.
Kim T; Moon JH; Ahn JS; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Tyndel MS; Shin MG; Lee YJ; Sohn SK; Park SK; Zhang Z; Kim HJ; Kim DDH
Blood; 2018 Oct; 132(15):1604-1613. PubMed ID: 30108064
[TBL] [Abstract][Full Text] [Related]
2. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
3. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
9. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T; Krahl R; Kahl C; Cross M; Scholl S; Wolf HH; Hähling D; Hegenbart U; Peter N; Schulze A; Florschütz A; Schmidt V; Reifenrath K; Zojer N; Junghanss C; Sayer HG; Maschmeyer G; Späth C; Hochhaus A; Fischer T; Al-Ali HK; Niederwieser D
Ann Hematol; 2021 Sep; 100(9):2387-2398. PubMed ID: 34232360
[TBL] [Abstract][Full Text] [Related]
12. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Morita K; Kantarjian HM; Wang F; Yan Y; Bueso-Ramos C; Sasaki K; Issa GC; Wang S; Jorgensen J; Song X; Zhang J; Tippen S; Thornton R; Coyle M; Little L; Gumbs C; Pemmaraju N; Daver N; DiNardo CD; Konopleva M; Andreeff M; Ravandi F; Cortes JE; Kadia T; Jabbour E; Garcia-Manero G; Patel KP; Futreal PA; Takahashi K
J Clin Oncol; 2018 Jun; 36(18):1788-1797. PubMed ID: 29702001
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
14. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
Ahn JS; Kim T; Jung SH; Ahn SY; Jung SY; Song GY; Kim M; Yang DH; Lee JJ; Choi S; Lee JY; Park SK; Moon JH; Lee HY; Kim KH; Cai Y; Yi SY; Novitzky-Basso I; Zhang Z; Kim HJ; Kim DDH
Bone Marrow Transplant; 2021 May; 56(5):1159-1170. PubMed ID: 33279940
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
17. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
[TBL] [Abstract][Full Text] [Related]
18. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
19. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]